Cross-species/cross-modality physiologically based pharmacokinetics for biologics: 89Zr-labelled albumin-binding domain antibody GSK3128349 in humans

References

• Carter PJ, Lazar GA. Next generation antibody drugs: pursuit of the ‘high-hanging fruit’. Nat Rev Drug Discov. 2017;17:197–11.
   PubMed Web of Science ®Google Scholar
• Lagassé HAD, Alexaki A, Simhadri VL, Katagiri NH, Jankowski W, Sauna ZE, Kimchi-Sarfaty C. Recent advances in (therapeutic protein) drug development. F1000Res. 2017;6:113. doi:https://doi.org/10.12688/f1000research.9970.1.
   PubMedGoogle Scholar
• Ward ES, Gussow D, Griffiths AD, Jones PT, Winter G. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature. 1989;341:544–46. doi:https://doi.org/10.1038/341544a0.
   PubMed Web of Science ®Google Scholar
• Jespers L, Schon O, Famm K, Winter G. Aggregation-resistant domain antibodies selected on phage by heat denaturation. Nat Biotechnol. 2004;22:1161–65. doi:https://doi.org/10.1038/nbt1000.
   PubMed Web of Science ®Google Scholar
• Sheridan C. Ablynx’s nanobody fragments go places antibodies cannot. Nat Biotechnol. 2017;35:1115. doi:https://doi.org/10.1038/nbt1217-1115.
   PubMed Web of Science ®Google Scholar
• Ellerman D. Bispecific T-cell engagers: towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety. Methods. 2019;154:102–17. doi:https://doi.org/10.1016/j.ymeth.2018.10.026.
   PubMed Web of Science ®Google Scholar
• Wensel D, Sun Y, Li Z, Zhang S, Picarillo C, McDonagh T, Fabrizio D, Cockett M, Krystal M, Davis J, et al. Discovery and characterization of a novel CD4-binding adnectin with potent anti-HIV activity. Antimicrob Agents Chemother. 2017;61:e00508–17. doi:https://doi.org/10.1128/AAC.00508-17.
   PubMed Web of Science ®Google Scholar
• Plückthun A. Designed Ankyrin Repeat Proteins (DARPins): binding proteins for research, diagnostics, and therapy. Annu Rev Pharmacol Toxicol. 2015;55:489–511. doi:https://doi.org/10.1146/annurev-pharmtox-010611-134654.
   PubMed Web of Science ®Google Scholar
• Rothe C, Skerra A. Anticalin(®) proteins as therapeutic agents in human diseases. BioDrugs. 2018;32:233–43. doi:https://doi.org/10.1007/s40259-018-0278-1.
   PubMed Web of Science ®Google Scholar
• Boudousquie C, Bossi G, Hurst JM, Rygiel KA, Jakobsen BK, Hassan NJ. Polyfunctional response by ImmTAC (IMCgp100) redirected CD8(+) and CD4(+) T cells. Immunology. 2017;152:425–38. doi:https://doi.org/10.1111/imm.12779.
   PubMed Web of Science ®Google Scholar
• Morgan P, Van Der Graaf PH, Arrowsmith J, Feltner DE, Drummond KS, Wegner CD, Street SDA. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving phase II survival. Drug Discov Today. 2012;17:419–24.
   PubMed Web of Science ®Google Scholar
• Rippe B, Haraldsson B. Transport of macromolecules across microvascular walls: the two-pore theory. Physiol Rev. 1994;74:163–219. doi:https://doi.org/10.1152/physrev.1994.74.1.163.
   PubMed Web of Science ®Google Scholar
• Sepp A, Berges A, Sanderson A, Meno-Tetang G. Development of a physiologically based pharmacokinetic model for a domain antibody in mice using the two-pore theory. J Pharmacokinet Pharmacodyn. 2015;42:97–109. doi:https://doi.org/10.1007/s10928-014-9402-0.
   PubMed Web of Science ®Google Scholar
• Sepp A, Meno-Tetang G, Weber A, Sanderson A, Schon O, Berges A. Computer-assembled cross-species/cross-modalities two-pore physiologically based pharmacokinetic model for biologics in mice and rats. J Pharmacokinet Pharmacodyn. 2019;46:339–59. doi:https://doi.org/10.1007/s10928-019-09640-9.
   PubMed Web of Science ®Google Scholar
• Thorneloe KS, Sepp A, Zhang S, Galinanes-Garcia L, Galette P, Al-Azzam W, Vugts DJ, van Dongen G, Elsinga P, Wiegers J, et al. The biodistribution and clearance of AlbudAb, a novel biopharmaceutical medicine platform, assessed via PET imaging in humans. EJNMMI Res. 2019;9:45. doi:https://doi.org/10.1186/s13550-019-0514-9.
   PubMed Web of Science ®Google Scholar
• Kim J, Hayton WL, Robinson JM, Anderson CL. Kinetics of FcRn-mediated recycling of IgG and albumin in human: pathophysiology and therapeutic implications using a simplified mechanism-based model. Clin Immunol. 2007;122:146–55. doi:https://doi.org/10.1016/j.clim.2006.09.001.
   PubMed Web of Science ®Google Scholar
• Waldmann TA, Strober W. Metabolism of immunoglobulins. Prog Allergy. 1969;13:1–110.
   PubMedGoogle Scholar
• Waldmann TA, Terry WD. Familial hypercatabolic hypoproteinemia. A disorder of endogenous catabolism of albumin and immunoglobulin. J Clin Invest. 1990;86:2093–98. doi:https://doi.org/10.1172/JCI114947.
   PubMed Web of Science ®Google Scholar
• Wani MA, Haynes LD, Kim J, Bronson CL, Chaudhury C, Mohanty S, Waldmann TA, Robinson JM, Anderson CL. Familial hypercatabolic hypoproteinemia caused by deficiency of the neonatal Fc receptor, FcRn, due to a mutant β2-microglobulin gene. Proc Natl Acad Sci USA. 2006;103:5084–89. doi:https://doi.org/10.1073/pnas.0600548103.
   PubMed Web of Science ®Google Scholar
• Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93:2645–68. doi:https://doi.org/10.1002/jps.20178.
   PubMed Web of Science ®Google Scholar
• Fan -Y-Y, Avery LB, Wang M, O’Hara DM, Leung S, Neubert H. Tissue expression profile of human neonatal Fc receptor (FcRn) in Tg32 transgenic mice. mAbs. 2016;8:848–53. doi:https://doi.org/10.1080/19420862.2016.1178436.
   PubMed Web of Science ®Google Scholar
• Cameron J, Sleep D, Sandlie I, Andersen JT Pharmacokinetic animal model. WO 2014/125082, Google Patents; 2014.
   Google Scholar
• Beeken WL, Volwiler W, Goldsworthy PD, Garby LE, Reynolds WE, Stogsdill R, Stemler RS. Studies of I-131-albumin catabolism and distribution in normal young male adults. J Clin Invest. 1962;41:1312–33. doi:https://doi.org/10.1172/JCI104594.
   PubMed Web of Science ®Google Scholar
• Anderson CL, Chaudhury C, Kim J, Bronson CL, Wani MA, Mohanty S. Perspective – fcRn transports albumin: relevance to immunology and medicine. Trends Immunol. 2006;27:343–48. doi:https://doi.org/10.1016/j.it.2006.05.004.
   PubMed Web of Science ®Google Scholar
• Levitt DG, Levitt MD. Human serum albumin homeostasis: a new look at the roles of synthesis, catabolism, renal and gastrointestinal excretion, and the clinical value of serum albumin measurements. Int J Gen Med. 2016;9:229–55. doi:https://doi.org/10.2147/IJGM.S102819.
   PubMed Web of Science ®Google Scholar
• Vincent J-L, Russell JA, Jacob M, Martin G, Guidet B, Wernerman J, Roca R, McCluskey SA, Gattinoni L. Albumin administration in the acutely ill: what is new and where next? Crit Care. 2014;18:231. doi:https://doi.org/10.1186/cc13991.
   PubMed Web of Science ®Google Scholar
• Tojo A, Kinugasa S. Mechanisms of glomerular albumin filtration and tubular reabsorption. Int J Nephrol. 2012;2012:9. doi:https://doi.org/10.1155/2012/481520.
   Google Scholar
• Norden AGW, Lapsley M, Lee PJ, Pusey CD, Scheinman SJ, Tam FWK, Thakker RV, Unwin RJ, Wrong O. Glomerular protein sieving and implications for renal failure in Fanconi syndrome. Kidney Int. 2001;60:1885–92. doi:https://doi.org/10.1046/j.1523-1755.2001.00016.x.
   PubMed Web of Science ®Google Scholar
• Rutili G, Arfors K-E. Protein concentration in interstitial and lymphatic fluids from the subcutaneous tissue. Acta Physiol Scand. 1977;99:1–8. doi:https://doi.org/10.1111/j.1748-1716.1977.tb10345.x.
   PubMedGoogle Scholar
• Morgan P, Brown DG, Lennard S, Anderton MJ, Barrett JC, Eriksson U, Fidock M, Hamrén B, Johnson A, March RE, et al. Impact of a five-dimensional framework on R&D productivity at AstraZeneca. Nat Rev Drug Discov. 2018;17:167–181.
   PubMed Web of Science ®Google Scholar
• Bayliss MK, Butler J, Feldman PL, Green DVS, Leeson PD, Palovich MR, Taylor AJ. Quality guidelines for oral drug candidates: dose, solubility and lipophilicity. Drug Discov Today. 2016;21:1719–27. doi:https://doi.org/10.1016/j.drudis.2016.07.007.
   PubMed Web of Science ®Google Scholar
• Petitcollin A, Bensalem A, Verdier M-C, Tron C, Lemaitre F, Paintaud G, Bellissant E, Ternant D. Modelling of the time-varying pharmacokinetics of therapeutic monoclonal antibodies: a literature review. Clin Pharmacokinet. 2020;59:37–49. doi:https://doi.org/10.1007/s40262-019-00816-7.
   PubMed Web of Science ®Google Scholar
• Shah DK, Betts AM. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn. 2012;39:67–86. doi:https://doi.org/10.1007/s10928-011-9232-2.
   PubMed Web of Science ®Google Scholar
• Nguyen A, Reyes AE, Zhang M, McDonald P, Wong WLT, Damico LA, Dennis MS. The pharmacokinetics of an albumin-binding Fab (AB.Fab) can be modulated as a function of affinity for albumin. Protein Eng Des Sel. 2006;19:291–97. doi:https://doi.org/10.1093/protein/gzl011.
   PubMed Web of Science ®Google Scholar
• Hoefman S, Ottevaere I, Baumeister J, Sargentini-Maier ML. Pre-clinical intravenous serum pharmacokinetics of albumin binding and non-half-life extended nanobodies®. Antibodies. 2015;4:141–56. doi:https://doi.org/10.3390/antib4030141.
   Web of Science ®Google Scholar
• Holt LJ, Basran A, Jones K, Chorlton J, Jespers LS, Brewis ND, Tomlinson IM. Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs. Protein Eng Des Sel. 2008;21:283–88. doi:https://doi.org/10.1093/protein/gzm067.
   PubMed Web of Science ®Google Scholar
• Herring C, Schon O. AlbudAb™ technology platform–versatile albumin binding domains for the development of therapeutics with tunable half-lives. Therapeutic Proteins: Wiley-VCH Verlag GmbH & Co. KGaA; 2012. p. 249–68.
   Google Scholar
• Rothschild MA, Bauman A, Yalow RS, Berson SA. Tissue distribution of I131 labeled human serum albumin following intravenous administration. J Clin Invest. 1955;34:1354–58. doi:https://doi.org/10.1172/JCI103183.
   PubMed Web of Science ®Google Scholar
• Ellmerer M, Schaupp L, Brunner GA, Sendlhofer G, Wutte A, Wach P, Pieber TR. Measurement of interstitial albumin in human skeletal muscle and adipose tissue by open-flow microperfusion. Am J Physiol Endocrinol Metab. 2000;278:E352–E6. doi:https://doi.org/10.1152/ajpendo.2000.278.2.E352.
   PubMed Web of Science ®Google Scholar
• Hladky SB, Barrand MA. Mechanisms of fluid movement into, through and out of the brain: evaluation of the evidence. Fluids Barriers CNS. 2014;11:26. doi:https://doi.org/10.1186/2045-8118-11-26.
   PubMedGoogle Scholar
• Andersen JT, Daba MB, Berntzen G, Michaelsen TE, Sandlie I. Cross-species binding analyses of mouse and human neonatal fc receptor show dramatic differences in immunoglobulin G and albumin binding. J Biol Chem. 2010;285:4826–36. doi:https://doi.org/10.1074/jbc.M109.081828.
   PubMed Web of Science ®Google Scholar
• Andersen JT, Cameron J, Plumridge A, Evans L, Sleep D, Sandlie I. Single-chain variable fragment albumin fusions bind the neonatal Fc receptor (FcRn) in a species dependent manner: implications for in vivo half-life evaluation of albumin-fusion therapeutics. J Biol Chem. 2013;288:24277–85. doi:https://doi.org/10.1074/jbc.M113.463000.
   PubMed Web of Science ®Google Scholar
• Andersen JT, Dalhus B, Viuff D, Thue Ravn B, Gunnarsen KS, Plumridge A, Bunting K, Antunes F, Williamson R, Athwal S, et al. Extending serum half-life of albumin by engineering FcRn binding. J Biol Chem. 2014;289:13492–502. doi:https://doi.org/10.1074/jbc.M114.549832.
   PubMed Web of Science ®Google Scholar
• Viuff D, Antunes F, Evans L, Cameron J, Dyrnesli H, Thue Ravn B, Stougaard M, Thiam K, Andersen B, Kjærulff S, et al. Generation of a double transgenic humanized neonatal Fc receptor (FcRn)/albumin mouse to study the pharmacokinetics of albumin-linked drugs. J Controlled Release. 2016;223:22–30. doi:https://doi.org/10.1016/j.jconrel.2015.12.019.
   PubMed Web of Science ®Google Scholar
• Nilsen J, Bern M, Sand KMK, Grevys A, Dalhus B, Sandlie I, Andersen JT. Human and mouse albumin bind their respective neonatal Fc receptors differently. Sci Rep. 2018;8:14648. doi:https://doi.org/10.1038/s41598-018-32817-0.
   PubMed Web of Science ®Google Scholar
• Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer. 2002;2:683. doi:https://doi.org/10.1038/nrc882.
   PubMed Web of Science ®Google Scholar
• Lamberts LE, Williams SP, Terwisscha van Scheltinga AGT, Lub-de Hooge MN, Schröder CP, Gietema JA, Brouwers AH, de Vries EGE. Antibody positron emission tomography imaging in anticancer drug development. J Clin Oncol. 2015;33:1491–504. doi:https://doi.org/10.1200/JCO.2014.57.8278.
   PubMed Web of Science ®Google Scholar
• van Dongen GAMS, Vosjan MJWD. Immuno-positron emission tomography: shedding light on clinical antibody therapy. Cancer Biother Radiopharm. 2010;25:375–85. doi:https://doi.org/10.1089/cbr.2010.0812.
   PubMed Web of Science ®Google Scholar
• Deri MA, Zeglis BM, Francesconi LC, Lewis JS. PET imaging with ⁸⁹Zr: from radiochemistry to the clinic. Nucl Med Biol. 2013;40:3–14. doi:https://doi.org/10.1016/j.nucmedbio.2012.08.004.
   PubMed Web of Science ®Google Scholar
• Vosjan MJWD, Perk LR, Visser GWM, Budde M, Jurek P, Kiefer GE, van Dongen GAMS. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat Protoc. 2010;5:739. doi:https://doi.org/10.1038/nprot.2010.13.
   PubMed Web of Science ®Google Scholar
• Holland JP, Divilov V, Bander NH, Smith-Jones PM, Larson SM, Lewis JS. 89Zr-DFO-J591 for immunopet of prostate-specific membrane antigen expression in vivo. J Nucl Med. 2010;51:1293–300. doi:https://doi.org/10.2967/jnumed.110.076174.
   PubMed Web of Science ®Google Scholar
• Haraldsson B, Nystrom J, Deen WM. Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev. 2008;88:451–87. doi:https://doi.org/10.1152/physrev.00055.2006.
   PubMed Web of Science ®Google Scholar
• Haraldsson B, Jeansson M. Glomerular filtration barrier. Curr Opin Nephrol Hypertens. 2009;18:331–35. doi:https://doi.org/10.1097/MNH.0b013e32832c9dba.
   PubMed Web of Science ®Google Scholar
• Comper WD, Deen WM, Haraldsson B. Resolved: normal glomeruli filter nephrotic levels of albumin. J Am Soc Nephrol. 2008;19:427–32. doi:https://doi.org/10.1681/ASN.2007090997.
   PubMed Web of Science ®Google Scholar
• Raavé R, Sandker G, Adumeau P, Jacobsen CB, Mangin F, Meyer M, Moreau M, Bernhard C, Da Costa L, Dubois A, et al. Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for 89Zr-immunoPET. Eur J Nucl Med Mol Imaging. 2019;46:1966–77. doi:https://doi.org/10.1007/s00259-019-04343-2.
   PubMed Web of Science ®Google Scholar
• Meijs WE, Herscheid JDM, Haisma HJ, Pinedo HM. Evaluation of desferal as a bifunctional chelating agent for labeling antibodies with Zr-89. Int J Rad Appl Instrum A. 1992;43:1443–47. doi:https://doi.org/10.1016/0883-2889(92)90170-J.
   PubMedGoogle Scholar
• Bensch F, Smeenk MM, van Es SC, de Jong JR, Schröder CP, Oosting SF, Lub-de Hooge MN, Menke-van der Houven van Oordt CW, Brouwers AH, Boellaard R, et al. Comparative biodistribution analysis across four different 89Zr-monoclonal antibody tracers-the first step towards an imaging warehouse. Theranostics. 2018;8:4295–304. doi:https://doi.org/10.7150/thno.26370.
   PubMed Web of Science ®Google Scholar
• Nakada T, Kwee IL. Fluid dynamics inside the brain barrier: current concept of interstitial flow, glymphatic flow, and cerebrospinal fluid circulation in the brain. Neuroscientist. 2018;25:155–66. doi:https://doi.org/10.1177/1073858418775027.
   PubMed Web of Science ®Google Scholar
• Chang H-Y, Wu S, Meno-Tetang G, Shah DK. A translational platform PBPK model for antibody disposition in the brain. J Pharmacokinet Pharmacodyn. 2019;46:319–38. doi:https://doi.org/10.1007/s10928-019-09641-8.
   PubMed Web of Science ®Google Scholar
• Iacob SA, Iacob DG. Ibalizumab targeting CD4 receptors, an emerging molecule in HIV therapy. Front Microbiol. 2017;8:2323. doi:https://doi.org/10.3389/fmicb.2017.02323.
   PubMed Web of Science ®Google Scholar
• Song R, Franco D, Kao C-Y, Yu F, Huang Y, Ho DD. Epitope mapping of ibalizumab, a humanized anti-CD4 monoclonal antibody with anti-HIV-1 activity in infected patients. J Virol. 2010;84:6935–42. doi:https://doi.org/10.1128/JVI.00453-10.
   PubMed Web of Science ®Google Scholar
• Jacobson JM, Kuritzkes DR, Godofsky E, DeJesus E, Larson JA, Weinheimer SP, Lewis ST. Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults. Antimicrob Agents Chemother. 2009;53:450–57. doi:https://doi.org/10.1128/AAC.00942-08.
   PubMed Web of Science ®Google Scholar
• Wong JK, Yukl SA. Tissue reservoirs of HIV. Curr Opin HIV AIDS. 2016;11:362–70. doi:https://doi.org/10.1097/COH.0000000000000293.
   PubMed Web of Science ®Google Scholar
• Ganusov VV. Strong inference in mathematical modeling: a method for robust science in the twenty-first century. Front Microbiol. 2016;7. doi:https://doi.org/10.3389/fmicb.2016.01131.
   Google Scholar
• Graf JF, Scholz BJ, Zavodszky MI. BioDMET: a physiologically based pharmacokinetic simulation tool for assessing proposed solutions to complex biological problems. J Pharmacokinet Pharmacodyn. 2012;39:37–54. doi:https://doi.org/10.1007/s10928-011-9229-x.
   PubMed Web of Science ®Google Scholar
• Wiig H, Gyenge C, Iversen PO, Gullberg D, Tenstad O. The role of the extracellular matrix in tissue distribution of macromolecules in normal and pathological tissues: potential therapeutic consequences. Microcirculation. 2008;15:283–96. doi:https://doi.org/10.1080/10739680701671105.
   PubMed Web of Science ®Google Scholar
• Garg A, Balthasar J. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn. 2007;34:687–709. doi:https://doi.org/10.1007/s10928-007-9065-1.
   PubMed Web of Science ®Google Scholar
• Hansen RJ, Balthasar JP. Pharmacokinetic/pharmacodynamic modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia. J Pharm Sci. 2003;92:1206–15. doi:https://doi.org/10.1002/jps.10364.
   PubMed Web of Science ®Google Scholar